Cefastad

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cefastad

What is Cefastad? An Overview

Cefastad is a prescription-only medicine that functions as an anti-infective for systemic use. It is a trade name for a product whose sole active component is the antibiotic Cefaclor (the INN), making it a single-ingredient oral preparation. This drug is primarily intended to target and eliminate harmful bacteria responsible for various infections within the body.


Quick Facts

Property Description
Active ingredient Cefaclor
Route of Administration Oral (by mouth)
Pharmacological class Second-generation cephalosporin antibiotic
Action Type Bactericidal (kills bacteria)
Origin Semisynthetic

What Type of Antibiotic is Cefastad?

Cefastad is classified as a semisynthetic beta-lactam antibiotic belonging to the second-generation cephalosporin group. This classification means the medicine is chemically derived from a natural core structure and is effective against a broad array of bacterial strains, including certain Gram-positive and Gram-negative organisms. Second-generation cephalosporins are clinically recognized for their versatility in addressing common, community-acquired bacterial infections.


What is Cefaclor's General Purpose and Action?

Cefaclor’s general purpose is to provide bactericidal treatment, meaning it actively kills the target bacteria causing an infection. The bactericidal action of cephalosporins results from the inhibition of bacterial cell-wall synthesis. This selective process is the core benefit, as it directly neutralizes the microbial threat, making the compound suitable for resolving infections like certain types of respiratory tract infections.


What Forms Does Cefastad Come In?

Cefastad is designed for oral administration and is available in multiple pharmaceutical preparations to accommodate various patient needs. The availability of forms such as standard capsules, extended-release tablets, and a liquid oral suspension is a differentiating factor, as it permits tailored use across different patient groups. The oral suspension is crucial for use in pediatric patient groups and others who require a liquid format, highlighting the brand's focus on comprehensive patient access.

Regulatory References

  1. U.S. National Library of Medicine (NIH)
  2. U.S. Food and Drug Administration (FDA)

What side effects are possible with Cefastad?

Possible side effects and safety information

The official safety profile for Cefastad (Cefaclor) defines the known adverse reactions by their physiological impact and documented rate of occurrence, strictly based on regulatory classification.

Adverse Reaction Classifications

Adverse reactions are grouped into System-Organ Classes. These include Gastrointestinal Disorders (e.g., diarrhea, nausea, vomiting), Blood and Lymphatic System Disorders (e.g., eosinophilia, thrombocytopenia), Nervous System Disorders (e.g., headache, dizziness), and Skin and Subcutaneous Tissue Disorders (e.g., rash, pruritus).

In terms of frequency, certain effects are classified as Common in regulatory documents, such as diarrhea and headache. Other events are classified as Rare or Uncommon, including more serious reactions.

Serious Safety Concerns and Specific Populations

The regulatory profile identifies several events as serious adverse reactions. These include severe allergic responses such as Anaphylaxis and severe skin conditions like Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Additionally, Pseudomembranous colitis, which may range from mild to life-threatening, is documented as a possible severe gastrointestinal complication that can occur during or after treatment.

Safety statements in official labeling emphasize particular considerations for certain groups. For example, caution is advised for patients with markedly impaired renal function due to a potentially greater risk of toxic reactions. Furthermore, serum sickness-like reactions are reported more frequently in children than in adults. The drug is contraindicated in patients with a known hypersensitivity to Cefaclor or any other cephalosporin antibiotic.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents state that an overdose of Cefastad (Cefaclor) may primarily result in gastrointestinal upset, including nausea, vomiting, diarrhea, and epigastric distress. The severity of these gastrointestinal effects is formally documented as dose-related. Beyond these manifestations, severe outcomes such as seizures and signs of neurotoxicity have been reported, representing a critical risk, especially for patients with impaired renal function due to high drug concentrations.

Immediate medical attention is required for any suspected overdose. Emergency services must be contacted immediately if symptoms involve collapse, trouble breathing, having a seizure, or the inability to be awakened.

Management is mainly supportive and symptomatic. Officially described supportive measures include gastric lavage for very large ingestions and the administration of activated charcoal to help reduce drug absorption. Additionally, official regulatory sources specify that advanced procedures like hemodialysis or forced diuresis have not been established as beneficial in treating Cefaclor overdose. The official profile underscores the need for urgent help to manage these dose-dependent systemic effects.

Therapeutic Uses of Cefastad

What Cefastad Treats: Main Uses and Benefits

Cefastad (Cefaclor) is an oral anti-infective that is commonly used to help with symptomatic support across various acute infections, which contributes to easing the overall symptom load. Its primary therapeutic role is in managing infections where symptoms are driven by susceptible bacteria.

The medication is considered relevant in contexts involving heightened systemic burden, and is commonly used to help with conditions that involve episodic or fluctuating manifestations, such as respiratory tract infections, acute otitis media (ear infections), uncomplicated skin and soft tissue infections, and urinary tract infections (UTIs).


Key Symptom Domains and Therapeutic Support

Cefaclor helps address symptom clusters that may become intense or disruptive, used in settings marked by temporary physiological imbalance (like fever and malaise) and symptoms related to inflammatory or irritative states (such as painful urination, sore throat, or earache). It is generally applied during phases when symptoms become more noticeable, providing support that helps ease the overall symptom burden.

“Cefastad is used to help with symptoms related to physical discomfort like sore throat, cough, chest congestion, and earache, contributing to easing the overall symptom load.”


Quick Fact: Support for Acute Symptom Manifestations

Therapeutic Focus Benefit to Patient
Systemic Symptoms Helps manage elevated body temperature (fever)
Localized Discomfort Supports in easing symptoms related to localized discomfort
Functional Stability Assists with maintaining comfort during symptomatic episodes

Regulatory References

  1. NIH DailyMed label overview

Eligibility and Restrictions for Use

Cefastad (Cefaclor) is an antibiotic approved for use in adults and pediatric patients one month of age and older. Regulatory documents clearly define populations who must not use the medicine and those who require conditional use.

Who Must Not Use Cefastad (Contraindications)

Cefastad is contraindicated and must not be used by any patient with a known hypersensitivity or allergy to Cefaclor, the cephalosporin class of antibiotics, or a severe allergic history to penicillin. Furthermore, infants under the age of one month are excluded because safety and efficacy are not established for this group. The medicine is also contraindicated in patients with Porphyria.

Conditions Requiring Restricted Use

Use is categorized as restricted or requires caution for certain populations. Patients with markedly impaired renal function or a history of gastrointestinal disease, particularly colitis, must use the medicine only under special consideration, as explicitly stated in the label. For pregnant or nursing women, use is generally not recommended unless officially classified as clearly needed.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information documents key interactions involving Cefaclor. These interactions primarily fall into the categories of altered exposure, changes to coagulation parameters, and increased risk of organ toxicity, all based on documented pharmacokinetic and pharmacodynamic outcomes.


Documented Pharmacokinetic and Pharmacodynamic Interactions

Interacting Substance/Class Official Documented Outcome Classification
Probenecid Inhibits renal tubular secretion, leading to increased and prolonged serum concentrations of Cefaclor. Exposure-Modifying
Oral Anticoagulants (e.g., Warfarin) Associated with documented reports of increased prothrombin time and potential bleeding risk. Pharmacodynamic
Nephrotoxic Agents (e.g., Aminoglycosides) May increase the risk or severity of nephrotoxicity (kidney damage). Pharmacodynamic
Bacteriostatic Antibacterials Regulatory information notes the potential for antagonism when co-administered. Pharmacodynamic

Restrictions and Special Considerations

Co-administration with aluminum- or magnesium-containing antacids is documented to diminish the extent of Cefaclor absorption from the extended-release formulation. Official labeling requires that these antacids be administered 1 hour before or 1 hour after the Cefaclor extended-release dose. The risk of CNS toxicity, including seizures, is noted as heightened in patients with reduced renal function if appropriate dosage modifications are not implemented. Additionally, Cefaclor can produce a false-positive reaction when specific copper reduction methods are used for urinary glucose tests.

Mechanism of Action

Targeting the Bacterial Structural Blueprint

Cefastad's mechanism centers on the irreversible inhibition of Penicillin-Binding Proteins (PBPs), which are bacterial enzymes essential for building the cell wall. By acting as a suicide inhibitor, the drug's beta-lactam structure permanently deactivates the PBP's transpeptidase function, thus stopping the peptidoglycan cross-linking required for structural integrity.

The Bactericidal Cascade of Cell Lysis

The structural breakdown caused by PBP inactivation immediately compromises the bacteria's protective shell, leading to a catastrophic loss of osmotic stability. This process often triggers the activation of the bacteria's own autolytic enzymes (autolysins). The combined effect of structural failure and autolysis results in rapid cell lysis (rupture) and death, defining Cefastad’s bactericidal action against the microbial population.

Mechanistic Constraints: Bacterial Defense

The drug's action can be functionally constrained when bacteria deploy defense mechanisms, primarily the production of beta-Lactamase enzymes that hydrolyze and inactivate the Cefaclor molecule before it can reach its PBP target. Alternatively, certain strains may possess structurally modified PBPs with reduced affinity, which prevents the drug from initiating its lethal cascade.

Dosage and Administration Information

Official Administration Guidelines

Cefastad (cephalexin) is an antibiotic intended strictly for oral administration in the form of capsules, tablets, or reconstituted oral suspension. It is acid-stable and may be administered without regard to meals (with or without food).


Dosage Regimens and Frequency

  • Adults (15 years): The usual dose is 250 mg every 6 hours or 500 mg every 12 hours. For severe cases, the dose may be increased, not to exceed 4 grams daily in divided doses.
  • Pediatric Patients (1 year): The total daily dose is calculated based on body weight, typically 25 to 50 mg/kg/day, given in equally divided doses. For specific conditions like otitis media, the dose may be higher.
  • Duration: Therapy generally lasts 7 to 14 days. For infections caused by beta-hemolytic streptococci, treatment must be continued for a minimum of 10 days.

Preparation and Special Conditions

Condition Instruction
Oral Suspension Must be shaken well before each use after initial reconstitution.
Renal Impairment Dosage requires adjustment in patients with impaired kidney function (e.g., Creatinine Clearance lt 60 mL/min). For instance, the maximum daily dose should not exceed 1 gram for CrCl 30 to 59 mL/min.
Missed Dose If a dose is missed, take it as soon as possible, unless it is almost time for the next scheduled dose; in that case, the missed dose should be skipped. Do not double doses.
Completion of Course The full course of therapy must be completed exactly as prescribed, even if the patient feels better early, to reduce the development of drug-resistant bacteria.

Recent Clinical Evidence

Research evidence / Overview of Studies for Cefastad

This section describes the types of scientific research that was studied for Cefastad (Cefaclor) and what those studies have monitored. This information is derived from official sources, including large-scale clinical trials and comprehensive reviews of the evidence, and is not a substitute for medical guidance.


Research Examining Respiratory Tract Infections

Cefastad was studied for its application in conditions characterized by fluctuating or episodic manifestations such as common upper and lower respiratory tract infections. The evidence base is primarily built upon Randomized Controlled Trials (RCTs) and subsequent meta-analyses. These studies monitored outcomes related to clinical cure rates (resolution of symptoms like fever and cough) and bacteriological eradication rates.

Findings describe patterns observed in the studies where clinical success rates for Cefaclor were observed in alignment with patterns described in the control groups. Research was studied for short-term clinical endpoints, meaning long-term outcomes are not fully established, and there is limited information on recurrence patterns long after the antibiotic course is finished.


Research Examining Acute Otitis Media (Ear Infections)

Research exploring short-term symptom changes in acute otitis media (AOM) primarily focused on pediatric patients (children). The main study types available include multiple RCTs that examined endpoints such as the resolution of ear pain and outcomes related to localized discomfort.

The studies reported that Cefaclor's clinical cure rates in this population were studied against the patterns observed in prespecified comparator groups. What remains uncertain is that specific susceptibility breakpoints for certain pathogens in AOM may not align with the standard criteria, which suggests a gap in understanding drug effectiveness against particular bacterial strains.


What Research Still Seeks to Clarify About Cefastad

Scientific reviews of Cefaclor synthesize the body of available evidence by also highlighting areas where certainty remains low or where more research is ongoing. Key limitations data show patterns related to include the age of some pivotal evidence and the fact that results apply only to the populations studied—primarily those with uncomplicated or mild-to-moderate infections. Comparative evidence is limited against many newer agents for all indications.

Key Studies & References

  1. Label: CEFACLOR suspension (Official Regulatory Monograph) - DailyMed - NIH
  2. Cefaclor: MedlinePlus Drug Information
  3. Cefaclor revisited (Nathwani & Wood, 2004) - Review of efficacy in respiratory tract infections

Frequently Asked Questions (FAQ)

Common questions about Cefastad (FAQ)

Q: Is Cefastad used for long-term conditions?

Cefastad is generally used for a short duration of time. According to official product information, the typical course of treatment lasts between 7 and 14 days. The drug's approved uses and prescribing information do not indicate its use for long-term conditions.


Q: Can Cefastad interact with pain relievers I take occasionally?

Official regulatory documents specify known interactions with certain medications, such as some anticoagulants or gout medicines. However, the official prescribing information does not typically list comprehensive interaction data for all common, occasionally used pain relievers. Information regarding the use of pain relief medication should be discussed with a qualified healthcare provider.


Q: What happens if I take Cefastad with my blood pressure medicine?

Regulatory information focuses on specific interactions that can affect kidney function or alter blood clotting parameters. Official documents do not cite a general interaction that applies to all types of blood pressure medications. Information about the combination of medications should be reviewed by a qualified healthcare professional.


Q: How quickly does Cefastad usually start working?

Cefastad begins its work soon after it is taken. Regulatory information indicates that the peak concentration of the medicine in the bloodstream, which is when it is most available to fight the infection, is typically reached about one hour after the dose is taken.


Q: Are there any specific foods or drinks that interact with Cefastad?

The official guidelines state that Cefastad can be taken with or without food. However, specific interactions are documented with certain products, such as antacids containing aluminum or magnesium. The official instructions indicate that these products require specific timing adjustments relative to the Cefastad dose.


Q: Does Cefastad affect birth control pills?

Regulatory documents and official product labels do not list an interaction between Cefastad (Cefaclor) and oral contraceptive pills. Official information notes that issues like vomiting or severe diarrhea may necessitate discussion with a healthcare professional regarding contraceptive reliability.


Q: Why do some people experience mild headaches when taking Cefastad?

Headache is listed in the official safety profile as a common adverse reaction associated with Cefastad. While the official documentation confirms that this effect is known to occur, the specific biological mechanism or cause for why certain individuals experience it is generally not detailed in the regulatory summary.


Q: Can Cefastad be used to treat viral infections?

No. Cefastad is classified as an antibacterial agent, meaning its purpose is to fight infections caused by susceptible bacteria. According to the official prescribing information, it is not indicated for the treatment of infections caused by viruses.


Q: How long does Cefastad stay in your system after the last dose?

Regulatory information provides the drug's elimination half-life, which describes the rate at which it is removed from the body. For Cefastad, this is typically about 0.6 to 0.9 hours. This short time suggests the drug is processed relatively quickly by the body.


Q: What is the research evidence for Cefastad's effectiveness?

Studies documented in official sources have examined Cefastad's use in specific bacterial infections, such as those of the respiratory tract and middle ear. The research monitored outcomes related to both clinical cure rates (resolution of symptoms) and bacteriological eradication rates (elimination of the bacteria) in these trials.


Q: What are the general guidelines for using Cefastad in older adults?

Regulatory labeling indicates that the dosage for older adults generally follows standard adult recommendations. However, official information advises caution for this population due to the higher likelihood of reduced kidney function, which may necessitate a dosage adjustment.


Q: Is Cefastad often prescribed for skin infections?

Yes, according to the official prescribing information, Cefastad is approved for the treatment of skin and skin structure infections when they are caused by susceptible organisms. This is one of the key conditions the drug is officially indicated to treat.


Q: Can Cefastad interact with herbal supplements?

The official regulatory information focuses on documented interactions with other prescription medications and certain compounds. However, official labeling does not typically contain comprehensive interaction data for all herbal or dietary supplements.


Q: Are there long-term side effects associated with Cefastad use?

The official safety profile lists documented adverse reactions but does not typically classify them as 'long-term' effects. Scientific reviews note that while short-term clinical outcomes have been well-studied, long-term outcomes following treatment are not fully established in the current body of evidence.


Q: What makes Cefastad different from penicillin?

Cefastad belongs to the cephalosporin class of antibiotics, which is chemically distinct from the penicillin class, although both are beta-lactam antibiotics. Official information documents differences in their binding to bacterial proteins and lists a warning regarding cross-hypersensitivity in patients with severe penicillin allergies.


Q: Does Cefastad impact liver function?

Yes, regulatory documentation indicates a potential impact on liver function. Official sources list rare adverse reactions, such as transient hepatitis (a temporary swelling of the liver) and cholestatic jaundice, which are documented impacts on the liver.


Q: Does Cefastad affect sleep?

The safety profile lists some documented adverse reactions related to the central nervous system, such as nervousness. While the official label may not specifically use the term 'sleep affect', these types of nervous system effects are generally associated with potential disturbances to sleep patterns.


Q: Can I drive or operate machinery while taking Cefastad?

The official label advises caution when driving or operating machinery. This warning is included because known side effects of Cefastad, such as dizziness or headache, may potentially impair the performance of such tasks.


Q: Does Cefastad cause sensitivity to sunlight?

Yes, according to official documentation, sensitivity to sunlight (photosensitivity) or similar skin reactions is listed as a rare or uncommon adverse event. Photosensitivity is a documented possibility associated with the medication.


Q: What is the difference between an allergy and a side effect of Cefastad?

Official regulatory documents describe side effects (adverse reactions) as expected or common unwanted effects like nausea or diarrhea. Allergic reactions, in contrast, are listed separately as serious safety concerns (like Anaphylaxis). Allergic reactions are generally recognized as safety concerns that require professional attention, distinct from the general list of adverse reactions.


Q: How is the safety profile of Cefastad generally described in medical documents?

The safety profile is described in official medical documents through a list of documented adverse reactions, including common effects like headache and diarrhea. The documents also include high-level warnings that highlight the potential for serious complications, such as severe hypersensitivity reactions and Pseudomembranous Colitis.


Q: Can Cefastad be crushed or split if the patient has trouble swallowing?

The ability to crush or split Cefastad depends entirely on the specific form prescribed. Official handling instructions specify that certain formulations, particularly extended-release tablets, are not intended to be crushed or chewed, as this can alter the drug's release characteristics.


Q: Is Cefastad suitable for use in people with asthma?

The official label does not list asthma as a contraindication for Cefastad. However, caution is required for patients with a general history of allergies, and this should be considered. The drug is contraindicated for anyone with a known allergy to Cefaclor or any cephalosporin.


Q: What does the official label say about Cefastad and alcohol?

Official regulatory documentation does not currently specify a known clinical interaction between Cefaclor and alcohol that requires a general prohibition on the label. Information regarding alcohol consumption should be reviewed with a qualified healthcare professional.


Q: Do studies suggest any specific populations might respond better to Cefastad?

Studies documented in regulatory summaries report observed success rates based on the specific populations that were studied. For example, evidence exists regarding its use in pediatric patients for middle ear infections. This means that the research indicates certain response patterns based on the populations studied.


Q: Can Cefastad cause confusion or mood changes?

Yes, official documentation lists certain central nervous system (CNS) events as documented adverse reactions. These can include feelings of nervousness or confusion, and in some cases, reversible hyperactivity has been reported.


Q: Why is Cefastad only available by prescription?

Cefastad is a prescription-only medicine because its proper use requires a professional diagnosis of a susceptible bacterial infection. This restriction is necessary to prevent improper use and reduce the significant public health risk associated with the development of drug-resistant bacteria.


Q: What were the key findings in the original Cefastad research trials?

The pivotal research trials established key factual findings related to the drug's approved uses. Official summaries contain statements confirming the successful establishment of clinical cure and bacteriological eradication (meaning the bacteria were eliminated) within the studied patient populations.

How should Cefastad be stored and disposed of?

How to Store and Dispose of Cefaclor (Cefastad)

Official regulatory labeling dictates specific storage and disposal requirements for Cefaclor formulations to maintain product stability and safety.


Storage Requirements

Dosage Form Temperature and Protection
Capsules/Tablets Store at Controlled Room Temperature (20 C to 25 C) and protect from excess heat and moisture.
Oral Suspension (Reconstituted) Must be stored in the refrigerator and discarded 14 days after mixing.

All forms must be kept in the original, tightly closed container and protected from freezing. It is a mandatory requirement to store the medicine out of the sight and reach of children.


Disposal

Expired or unused Cefaclor should be disposed of via an authorized drug take-back program. If this option is unavailable, the medication must be mixed with an unappealing substance and placed in a sealed bag for disposal in household trash. It should not be flushed down the toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cefastad found in:

A-Z Index: